The FTO (fat mass and obesity-associated) antibody is a critical tool for studying the FTO protein, an enzyme encoded by the *FTO* gene located on human chromosome 16. First linked to obesity through genome-wide association studies, FTO gained prominence for its role in regulating energy homeostasis, metabolism, and adipogenesis. Structurally, FTO functions as an RNA demethylase, primarily targeting N6-methyladenosine (m6A) and other RNA modifications, influencing mRNA splicing, stability, and translation. Its involvement in epigenetic regulation connects it to diverse physiological processes and diseases, including obesity, diabetes, cancer, and neurological disorders.
FTO antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunoprecipitation to detect protein expression, localization, and interactions. Researchers rely on these antibodies to explore tissue-specific FTO expression patterns, its dysregulation in metabolic syndromes, and its oncogenic or tumor-suppressive roles in different cancers. Validating antibody specificity is crucial, often achieved via knockout cell lines or siRNA-mediated FTO knockdown. Commercial FTO antibodies are typically raised against specific epitopes (e.g., human FTO amino acid residues 300-500) and vary in host species (rabbit, mouse) or conjugate tags (e.g., HRP, fluorescent labels). Challenges include cross-reactivity with homologous proteins (e.g., ALKBH5) and ensuring consistent performance across experimental models. As interest in RNA epigenetics grows, FTO antibodies remain indispensable for unraveling its molecular mechanisms and therapeutic potential.